Intech Investment Management LLC Purchases Shares of 14,703 Cardlytics, Inc. (NASDAQ:CDLX)

Intech Investment Management LLC purchased a new position in shares of Cardlytics, Inc. (NASDAQ:CDLX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 14,703 shares of the company’s stock, valued at approximately $47,000.

Other large investors have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its position in shares of Cardlytics by 6.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 29,769 shares of the company’s stock worth $432,000 after acquiring an additional 1,774 shares during the last quarter. Canton Hathaway LLC grew its stake in Cardlytics by 95.7% during the 2nd quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock valued at $37,000 after purchasing an additional 2,200 shares in the last quarter. Check Capital Management Inc. CA increased its holdings in Cardlytics by 10.4% during the 3rd quarter. Check Capital Management Inc. CA now owns 50,650 shares of the company’s stock worth $162,000 after purchasing an additional 4,775 shares during the last quarter. Creative Planning raised its position in shares of Cardlytics by 35.4% in the 3rd quarter. Creative Planning now owns 29,537 shares of the company’s stock valued at $95,000 after purchasing an additional 7,721 shares in the last quarter. Finally, Quest Partners LLC boosted its stake in shares of Cardlytics by 160.4% during the 2nd quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock valued at $147,000 after buying an additional 11,061 shares during the last quarter. 68.10% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Cardlytics news, CEO Amit Gupta sold 22,607 shares of the company’s stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the completion of the transaction, the chief executive officer now owns 178,519 shares in the company, valued at approximately $687,298.15. This represents a 11.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Alexis Desieno sold 25,118 shares of Cardlytics stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $3.43, for a total value of $86,154.74. Following the sale, the chief financial officer now directly owns 116,481 shares in the company, valued at approximately $399,529.83. This trade represents a 17.74 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 68,691 shares of company stock valued at $237,767 over the last three months. Company insiders own 4.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CDLX. Craig Hallum upgraded shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Northland Capmk lowered shares of Cardlytics from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 16th. Evercore ISI started coverage on Cardlytics in a research note on Friday, October 11th. They issued an “in-line” rating and a $4.00 price target for the company. Bank of America cut Cardlytics from a “neutral” rating to an “underperform” rating and cut their price objective for the company from $4.00 to $3.50 in a research note on Thursday, August 15th. Finally, Northland Securities lowered Cardlytics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $7.00 to $5.00 in a research report on Friday, August 16th. One analyst has rated the stock with a sell rating, five have given a hold rating and one has given a strong buy rating to the stock. According to MarketBeat, Cardlytics has an average rating of “Hold” and an average price target of $6.92.

Cardlytics Price Performance

CDLX opened at $3.95 on Monday. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 2.40. The company’s 50-day moving average price is $3.83 and its 200 day moving average price is $5.57. Cardlytics, Inc. has a fifty-two week low of $2.89 and a fifty-two week high of $20.52. The firm has a market cap of $200.75 million, a price-to-earnings ratio of -0.65 and a beta of 1.53.

Cardlytics (NASDAQ:CDLX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.18. The company had revenue of $67.06 million during the quarter, compared to analyst estimates of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The business’s revenue was down 15.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.26) earnings per share. As a group, sell-side analysts expect that Cardlytics, Inc. will post -1.52 earnings per share for the current year.

Cardlytics Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.